Zephyr Valve Eases Breathlessness in Severe Emphysema, Trial Analysis Shows

Zephyr Valve Eases Breathlessness in Severe Emphysema, Trial Analysis Shows
Pulmonx’s  Zephyr Endobronchial Valve significantly reduces breathlessness and improves physical activity and quality of life in people with severe emphysema, a post-hoc analysis of clinical trial data shows. The study, "Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels and Quality of Life at One Year," was published in the Annals of the American Thoracic Society. The Zephyr Valve is a device that can be used for bronchoscopic lung volume reduction (BLVR), a non-surgical way to block off diseased portions of the lung, allowing healthier parts to take in more air. Functionally, BLVR works the same way as lung volume reduction surgery, but without surgery to remove diseased tissues. Zephyr Valve is designed for people with emphysema — a severe form of chronic obstructive pulmonary disease (COPD) —who experience shortness of breath and are unable to perform their normal daily activities despite taking medications or oxygen therapy. BLVR with the Zephyr Valve was evaluated as a treatment for severe emphysema in the LIBERATE clinical trial (NCT01796392). This trial enrolled 190 people, randomized to either the BLVR using the valve (128 participants) plus standard care or standard of care (62 participants) only and followed for one year. Its main findings were previously reported, demonstrating clinically relevant benefits across multiple domains, including breathlessness and quality of life. (The Zephyr Value was approved by the FDA in 2018 for adults with severe emphysema.) Researchers now report the results of a post-hoc analysis (an analysis performed after-the-fact) of data from LIBERATE. Data gathered from questionnaires and assessments undertaken throughout the study period were analyzed. These covered three overarching c
Subscribe or log in to read the rest of this content.